Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben

    NEXT STORY
    Renalytix AI plc (“RenalytixAI” or the “Company”) Full Year Report
    PREV STORY
    Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.

    TEL AVIV, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced ...

    author_avatar
    NASDAQ Market News

    Changes to the Roche Corporate Executive Committee

    Basel, 10 December 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...

    author_avatar
    NASDAQ Market News

    Genetic Technologies and The Translational Genomics Research Institute of Phoenix, Arizona Sign Memorandum of Understanding

    author_avatar
    NASDAQ Market News